Clinical Trial Update: Levosimendan In Ambulatory Heart Failure Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating levosimendan in ambulatory heart failure patients (NYHA Class III/IV) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Medical University of Bialystok | Conditions: Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV | Phase 4 | Status: TERMINATED